Journal article
Manufacturing of primed mesenchymal stromal cells for therapy
Nature biomedical engineering, Vol.3(2), pp.90-104
02/2019
DOI: 10.1038/s41551-018-0325-8
PMID: 30944433
Abstract
Mesenchymal stromal cells (MSCs) for basic research and clinical applications are manufactured and developed as unique cell products by many different manufacturers and laboratories, often under different conditions. The lack of standardization of MSC identity has limited consensus around which MSC properties are relevant for specific outcomes. In this Review, we examine how the choice of media, cell source, culture environment and storage affects the phenotype and clinical utility of MSC-based products, and discuss the techniques better suited to prime MSCs with specific phenotypes of interest and the need for the continued development of standardized assays that provide quality assurance for clinical-grade MSCs. Bioequivalence between cell products and batches must be investigated rather than assumed, so that the diversity of phenotypes between differing MSC products can be accounted for to identify products with the highest therapeutic potential and to preserve their safety in clinical treatments.
Details
- Title: Subtitle
- Manufacturing of primed mesenchymal stromal cells for therapy
- Creators
- James Q Yin - Beijing Cancer Hospital, Translational Medicine, Beijing, China. jamesyin2010@126.comJun Zhu - Beijing Cancer Hospital, Translational Medicine, Beijing, ChinaJames A Ankrum - Roy J. Carver Department of Biomedical Engineering, Fraternal Order of Eagles Diabetes Research Center, The University of Iowa, Iowa City, IA, USA. james-ankrum@uiowa.edu
- Resource Type
- Journal article
- Publication Details
- Nature biomedical engineering, Vol.3(2), pp.90-104
- Publisher
- England
- DOI
- 10.1038/s41551-018-0325-8
- PMID
- 30944433
- ISSN
- 2157-846X
- eISSN
- 2157-846X
- Language
- English
- Date published
- 02/2019
- Academic Unit
- Roy J. Carver Department of Biomedical Engineering
- Record Identifier
- 9984000921202771
Metrics
59 Record Views